Ana M. Ortiz

1.3k citations
42 papers · 835 indexed · h-index 18

Ana M. Ortiz

42 papers receiving 810 citations

Peers

Ana M. Ortiz
Comparison fields: 5 of 97
  • Rheumatology 275
  • Virology 48
  • Hematology 105
  • Family Practice 18
  • Neurology 111
Replace Victor S. Sloan with:
Victor S. Sloan United States
Sriram Sampath India
U Schiemann Germany
B K Bang South Korea
Shirin Karimi Iran
Mira Barak Israel
Manathip Osiri Thailand
Foo Cheung United States
Shawn Rose United States
Sophia Georgiou Greece
Ana M. Ortiz relative to Victor S. Sloan United States Victor S. Sloan's profile →
Citations per field
00.5×8.5×
Victor S. Sloan · 1×
Citations per year

Countries citing papers authored by Ana M. Ortiz

Since Specialization
Citations

This map shows the geographic impact of Ana M. Ortiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana M. Ortiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana M. Ortiz more than expected).

Fields of papers citing papers by Ana M. Ortiz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana M. Ortiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana M. Ortiz. The network helps show where Ana M. Ortiz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ana M. Ortiz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ana M. Ortiz Line = papers co-authored together Ana M. Ortiz links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20233
2 20214
3 20195
4
Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.
201838
5 20186
6 201811
7 201729
8 201718
9 201631
10 201572
11 201422
12 201433
13 201323
14 201323
15 201313
16 201217
17 201257
18 201156
19 200222
20
Cyclosporin A inhibits CD69 expression induced on synovial fluid and peripheral blood lymphocytes by interleukin 15.
20008

About Ana M. Ortiz

Ana M. Ortiz is a scholar working on Microbiology, Rheumatology and Family Practice, having authored 42 papers that have together received 835 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (13 papers), Autoimmune and Inflammatory Disorders Research (6 papers), Systemic Lupus Erythematosus Research (6 papers), Peripheral Neuropathies and Disorders (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Alzheimer's disease research and treatments (3 papers), Dialysis and Renal Disease Management (2 papers) and Pharmaceutical studies and practices (2 papers). The work is most often cited by research in Rheumatology (275 citations), Virology (48 citations) and Hematology (105 citations). Ana M. Ortiz has collaborated with scholars based in Spain, Chile and United States. Frequent co-authors include Juan I. Jorquera, Isidoro González‐Álvaro, Montserrat Costa, Loreto Carmona, Juan J. Gómez‐Reino, Rosario García‐Vicuña, Alejandro Balsa, A Laffón, Rosa P. Gomariz and Giuseppe Melacini.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026